Related Experiment Videos
The new antibiotics
D Birnbaumer1, M Fernández-Frackelton
1Department of Medicine, University of California Los Angeles, Los Angeles, USA. dianeb@emedharbor.edu
Abstract:
It is easy to become overwhelmed by the amount of information available on the new antibiotics and difficult to keep abreast of the appropriate indications for each of them. For most patients with community-acquired infections, the first-line agent is usually not one of the newer agents, but a standard regimen, or at times, no antibiotic at all. The development of resistance is likely to parallel the extent to which these agents are prescribed. They should be used only when standard treatment fails, when compliance with treatment is a real and serious issue, or when the patient has a real allergic reaction to the standard regimen.
Insights
New antibiotics require careful consideration. Reserve novel agents for specific cases like treatment failure or allergies, not routine community-acquired infections, to combat resistance.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- The proliferation of new antibiotic agents presents a challenge for clinicians.
- Keeping up with appropriate indications for novel antimicrobials is complex.
Purpose of the Study:
- To provide guidance on the judicious use of new antibiotic agents.
- To emphasize the importance of standard regimens for common infections.
Main Methods:
- Review of current literature and clinical guidelines.
- Analysis of antibiotic resistance trends.
- Discussion of appropriate prescribing practices for novel antibiotics.
Main Results:
- Standard antibiotic regimens are typically first-line for community-acquired infections.
- Newer agents should be reserved for specific clinical scenarios.
Conclusions:
- Judicious use of new antibiotics is crucial to mitigate the development of antimicrobial resistance.
- Reserve novel agents for cases of standard treatment failure, poor compliance, or documented allergies.